

REMARKS

The Office Action mailed July 2, 2002 has been received and reviewed. The application is to be amended as previously set forth. All amendments are made without prejudice or disclaimer. Reconsideration is respectfully requested.

Restriction Requirement

Responsive to the restriction requirement, applicants have elected the claims of Group VI, *i.e.*, claims 18-20, drawn to a method of treating sepsis. This election is made without prejudice to pursue the remaining claims in a related application.

Species Election


Responsive to the species election, applicants provisionally elect Species 3, *i.e.*, SEQ ID NO: 3. This provisional election is made with traverse, since "normally ten sequences constitute a reasonable number for examination purposes" and only three sequences are presented. (M.P.E.P. § 803.04). Further, since SEQ ID NO: 3 is a fragment of SEQ ID NO: 2, which is a fragment of SEQ ID NO: 1, the three sequences are related and should be included together under 37 C.F.R. § 1.141.

Reconsideration and substantive examination of the application is requested.

CONCLUSION

If questions remain after consideration of the foregoing, the Office is kindly requested to contact applicants' attorney and the number of address given below.

Respectfully submitted,



Andrew F. Nilles
Registration No. 47,825
Attorney for Applicant(s)
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: October 2, 2002
AFN/afn
Document in ProLaw

MARKED UP VERSION OF CLAIMS TO SHOW CHANGES MADE

19. (Amended) The method [according to] of claim 18 wherein said immunoregulators comprise peptide and recombinant hCG.

20. (Amended) The method [according to] of claim 18 wherein the peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 and a functional fragment thereof.